TELA Bio (TELA) Common Equity (2018 - 2026)

TELA Bio has reported Common Equity for 9 years, with the latest figure at -$5.2 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 128.7% year-over-year to -$5.2 million; the trailing twelve-month figure through Mar 2026 stood at -$5.2 million (down 128.7% YoY), and the FY2025 full-year result was $6.3 million, down 77.82% from the prior year.
• Common Equity for Q1 2026 stood at -$5.2 million, down from $6.3 million in the prior quarter.
• The five-year high for Common Equity was $40.0 million in Q2 2023, with the low at -$6.3 million in Q3 2024.
• Average Common Equity over 5 years is $12.2 million, with a median of $10.0 million recorded in 2022.
• Year-over-year, Common Equity jumped 2694.36% in 2023 and sank 128.7% in 2026.
• Tracing TELA's Common Equity over 5 years: stood at $14.3 million in 2022, then jumped by 31.99% to $18.9 million in 2023, then surged by 50.72% to $28.5 million in 2024, then plunged by 77.82% to $6.3 million in 2025, then tumbled by 182.39% to -$5.2 million in 2026.
• The last three Common Equity figures came in at -$5.2 million (Q1 2026), $6.3 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.

Peer Comparison